ReviewMolecular biology reports2025
Revolutionizing vaccination: the marvel of nanovaccination technology.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Seasonal outbreaks of infectious diseases emphasise the critical need for the development of effective vaccines to address global healthcare challenges. Vaccines traditionally evolved using live attenuated organisms, killed organisms, and inactivated toxins. Despite the progression of traditional vaccines, improvement is needed due to toxicity and partial immunogenicity chances after multiple doses. Nanotechnology-based vaccines are now overcoming the gaps in traditional vaccines by enhancing their immunogenicity and reducing levels of toxicity. Nanocarrier-based vaccines reduce dosing frequency by enabling sustained antigen release, thereby minimising the need for booster doses required in conventional vaccines to achieve long-term immunity. The surface of nanocarriers can also be modified by phagocytic cells to increase their uptake for better antigen presentation and recognition and boost antibody production. As a result of better antigen recognition, the antibody production rate of nanocarrier-based vaccines is faster than that of traditional vaccines. Nanocarriers have a distinguished variety of sizes, shapes and compositions. They can also be used for the co-delivery of antigens and adjuvants. These advantageous nanocarriers are classified into various types based on their nature, like polymeric-based, lipid, and inorganic. In the case of solid nanocarriers, they protect against the degradation of the vaccine and improve its facilitation through gut related lymphoid tissues also mucosa linked lymphoid tissue. This review discussed the evolved platform of nanotechnology in vaccine development and its advantages over traditional vaccines. This paper also includes the classification of various nanocarriers, primarily focusing on nanovaccines developed for diseases such as hepatitis, malaria, COVID-19, influenza, human immunodeficiency virus, and cancer.
Indexed as
Identifiers
41003823What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.